登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月10日，Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-11

  • Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay

    James P Broughton, Xianding Deng, Guixia Yu, Clare L Fasching, Jasmeet Singh, Jessica Streithorst, Andrea Granados, Alicia Sotomayor-Gonzalez, Kelsey Zorn, Allan Gopez, Elaine Hsu, Wei Gu, Steven Miller, Chao-Yang Pan, Hugo Guevara, Debra Wadford, Janice Chen, Charles Y Chiu

    doi: https://doi.org/10.1101/2020.03.06.20032334

    Abstract

    An outbreak of novel betacoronavirus, SARS-CoV-2 (formerly named 2019-nCoV), began in Wuhan, China in December 2019 and the COVID-19 disease associated with infection has since spread rapidly to multiple countries. Here we report the development of SARS-CoV-2 DETECTR, a rapid (~30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARS-CoV-2. We validated this method using contrived reference samples and clinical samples from infected US patients and demonstrated comparable performance to the US CDC SARS-CoV-2 real-time RT-PCR assay.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.06.20032334v1
90浏览量
原文链接
相关报告

  • 《3月10日_美国Mammoth生物科学公司等开发一种基于DETECTR侧向层析检测的CRISPR系统用于快速检测SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-11
    • 1.时间：2020年3月10日 2.机构或团队：Mammoth生物科学公司、加州大学旧金山分校、加州公共卫生部 3.事件概要： 3月10日，medRxiv预印本发表了来自Mammoth生物科学公司、加州大学旧金山分校、加州公共卫生部的题为“Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay”的文章。 本文报道了SARS-CoV-2的DETECTR（DNA Endonuclease-TargetedCRISPR Trans Reporter，DNA内切酶靶向的CRISPR反式报告检测系统）的研究进展，这是一种快速（大约30min）、低成本、准确的基于侧向层析检测的CRISPR-Cas12系统，可用于检测SARS-CoV-2。使用人工参考样本和美国感染患者的临床样本验证了该方法，证明其性能与美国疾控中心的SARS-CoV-2实时RT-PCR检测试剂盒相当。 4.附件： 原文链接 https://www.medrxiv.org/content/10.1101/2020.03.06.20032334v1
    47浏览量
    原文链接

  • 《Nature，8月26日，Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-09-02
    • Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA Maturada Patchsung, Krittapas Jantarug, […]Chayasith Uttamapinant Nature Biomedical Engineering (2020) Abstract Nucleic acid detection by isothermal amplification and the collateral cleavage of reporter molecules by CRISPR-associated enzymes is a promising alternative to quantitative PCR. Here, we report the clinical validation of the specific high-sensitivity enzymatic reporter unlocking (SHERLOCK) assay using the enzyme Cas13a from Leptotrichia wadei for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—the virus that causes coronavirus disease 2019 (COVID-19)—in 154 nasopharyngeal and throat swab samples collected at Siriraj Hospital, Thailand. Within a detection limit of 42 RNA copies per reaction, SHERLOCK was 100% specific and 100% sensitive with a fluorescence readout, and 100% specific and 97% sensitive with a lateral-flow readout. For the full range of viral load in the clinical samples, the fluorescence readout was 100% specific and 96% sensitive. For 380 SARS-CoV-2-negative pre-operative samples from patients undergoing surgery, SHERLOCK was in 100% agreement with quantitative PCR with reverse transcription. The assay, which we show is amenable to multiplexed detection in a single lateral-flow strip incorporating an internal control for ribonuclease contamination, should facilitate SARS-CoV-2 detection in settings with limited resources.
    128浏览量
    原文链接